Literature DB >> 20977342

Murine model of Clostridium difficile infection with aged gnotobiotic C57BL/6 mice and a BI/NAP1 strain.

S W Pawlowski1, G Calabrese, G L Kolling, J Platts-Mills, R Freire, C AlcantaraWarren, B Liu, R B Sartor, R L Guerrant.   

Abstract

The increased incidence and severity of Clostridium difficile infection (CDI) in older adults (age, ≥65 years) corresponds with the emergence of the BI/NAP1 strain, making elucidation of the host immune response extremely important. We therefore infected germ-free C57BL/6 mice aged 7-14 months with a BI/NAP1 strain and monitored the mice for response. Infected mice were moribund 48-72 h after infection and developed gross and histological cecitis and colitis and elevated concentrations of keratinocyte chemoattractant, interleukin 1β, monocyte chemotactic protein 1, and granulocyte colony-stimulating factor and decreased levels of interferon γ, interleukin 12 p40, interleukin 12 p70, and interleukin 10 compared with controls. We conclude that aged, germ-free C57BL/6 mice are susceptible to fulminant CDI from a BI/NAP1 strain and represent a novel model to further elucidate the host immune response to acute CDI.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20977342      PMCID: PMC3057484          DOI: 10.1086/657086

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

Review 1.  Structure of the intestinal flora responsible for development of the gut immune system in a rodent model.

Authors:  Y Umesaki; H Setoyama
Journal:  Microbes Infect       Date:  2000-09       Impact factor: 2.700

2.  IL-12 induces IFN-gamma expression and secretion in mouse peritoneal macrophages.

Authors:  P Puddu; L Fantuzzi; P Borghi; B Varano; G Rainaldi; E Guillemard; W Malorni; P Nicaise; S F Wolf; F Belardelli; S Gessani
Journal:  J Immunol       Date:  1997-10-01       Impact factor: 5.422

3.  An epidemic, toxin gene-variant strain of Clostridium difficile.

Authors:  L Clifford McDonald; George E Killgore; Angela Thompson; Robert C Owens; Sophia V Kazakova; Susan P Sambol; Stuart Johnson; Dale N Gerding
Journal:  N Engl J Med       Date:  2005-12-01       Impact factor: 91.245

4.  Toxin gene analysis of a variant strain of Clostridium difficile that causes human clinical disease.

Authors:  S P Sambol; M M Merrigan; D Lyerly; D N Gerding; S Johnson
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

5.  Fecal lactoferrin, interleukin-1beta, and interleukin-8 are elevated in patients with severe Clostridium difficile colitis.

Authors:  T S Steiner; C A Flores; T T Pizarro; R L Guerrant
Journal:  Clin Diagn Lab Immunol       Date:  1997-11

6.  Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria.

Authors:  Sandra C Kim; Susan L Tonkonogy; Carol A Albright; Julia Tsang; Edward J Balish; Jonathon Braun; Mark M Huycke; R Balfour Sartor
Journal:  Gastroenterology       Date:  2005-04       Impact factor: 22.682

7.  Essential involvement of IFN-gamma in Clostridium difficile toxin A-induced enteritis.

Authors:  Yuko Ishida; Tsuneo Maegawa; Toshikazu Kondo; Akihiko Kimura; Yoichiro Iwakura; Shinichi Nakamura; Naofumi Mukaida
Journal:  J Immunol       Date:  2004-03-01       Impact factor: 5.422

8.  Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A.

Authors:  G Corthier; M C Muller; T D Wilkins; D Lyerly; R L'Haridon
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

9.  Differential effects of varying concentrations of clostridium difficile toxin A on epithelial barrier function and expression of cytokines.

Authors:  Shawinder S Johal; Katie Solomon; Sue Dodson; S Peter Borriello; Yashwant R Mahida
Journal:  J Infect Dis       Date:  2004-04-30       Impact factor: 5.226

10.  Relationship between levels of Clostridium difficile toxin A and toxin B and cecal lesions in gnotobiotic mice.

Authors:  A Vernet; G Corthier; F Dubos-Ramaré; A L Parodi
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

View more
  41 in total

1.  A small-molecule antivirulence agent for treating Clostridium difficile infection.

Authors:  Kristina Oresic Bender; Megan Garland; Jessica A Ferreyra; Andrew J Hryckowian; Matthew A Child; Aaron W Puri; David E Solow-Cordero; Steven K Higginbottom; Ehud Segal; Niaz Banaei; Aimee Shen; Justin L Sonnenburg; Matthew Bogyo
Journal:  Sci Transl Med       Date:  2015-09-23       Impact factor: 17.956

2.  Vancomycin Treatment Alters Humoral Immunity and Intestinal Microbiota in an Aged Mouse Model of Clostridium difficile Infection.

Authors:  Edward van Opstal; Glynis L Kolling; John H Moore; Christine M Coquery; Nekeithia S Wade; William M Loo; David T Bolick; Jae Hyun Shin; Loren D Erickson; Cirle A Warren
Journal:  J Infect Dis       Date:  2016-02-24       Impact factor: 5.226

3.  Mouse relapse model of Clostridium difficile infection.

Authors:  Xingmin Sun; Haiying Wang; Yongrong Zhang; Kevin Chen; Barbara Davis; Hanping Feng
Journal:  Infect Immun       Date:  2011-05-16       Impact factor: 3.441

4.  Using a Novel Lysin To Help Control Clostridium difficile Infections.

Authors:  Qiong Wang; Chad W Euler; Aurelia Delaune; Vincent A Fischetti
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

5.  Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice.

Authors:  Cirle A Warren; Edward J van Opstal; Mary S Riggins; Yuesheng Li; John H Moore; Glynis L Kolling; Richard L Guerrant; Paul S Hoffman
Journal:  Antimicrob Agents Chemother       Date:  2012-11-12       Impact factor: 5.191

6.  Cytokines Are Markers of the Clostridium difficile-Induced Inflammatory Response and Predict Disease Severity.

Authors:  Hua Yu; Kevin Chen; Ying Sun; Mihaela Carter; Kevin W Garey; Tor C Savidge; Sridevi Devaraj; Mary Elizabeth Tessier; Erik C von Rosenvinge; Ciaran P Kelly; Marcela F Pasetti; Hanping Feng
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

7.  The role of purified Clostridium difficile glucosylating toxins in disease pathogenesis utilizing a murine cecum injection model.

Authors:  Yongrong Zhang; Zhiyong Yang; Si Gao; Therwa Hamza; Harris G Yfantis; Michael Lipsky; Hanping Feng
Journal:  Anaerobe       Date:  2017-10-12       Impact factor: 3.331

8.  Contribution of adenosine A(2B) receptors in Clostridium difficile intoxication and infection.

Authors:  Cirle A Warren; Yuesheng Li; Gina M Calabrese; Rosemayre S Freire; Snjezana Zaja-Milatovic; Edward van Opstal; Robert A Figler; Joel Linden; Richard L Guerrant
Journal:  Infect Immun       Date:  2012-10-08       Impact factor: 3.441

9.  Intestinal epithelial restitution after TcdB challenge and recovery from Clostridium difficile infection in mice with alanyl-glutamine treatment.

Authors:  Raphael S Rodrigues; Renato A C Oliveira; Yuesheng Li; Snjezana Zaja-Milatovic; Lourrany B Costa; Manuel B Braga Neto; Glynis L Kolling; Aldo A Lima; Richard L Guerrant; Cirle Alcantara Warren
Journal:  J Infect Dis       Date:  2013-01-28       Impact factor: 5.226

Review 10.  Neutrophil-mediated inflammation in the pathogenesis of Clostridium difficile infections.

Authors:  Shinsmon Jose; Rajat Madan
Journal:  Anaerobe       Date:  2016-04-05       Impact factor: 3.331

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.